Immune biomarkers in immunotherapeutic trials for type 1 diabetes: Cui prodest?

Diabetes and Metabolism

Volumn 38, Issue 5, 2012, Pages 379-385

  Culina, S ^a,b   Mallone, R ^a,b,c  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antigen; Immunological strategies antibodies; Islet; Review; T cells; Therapy; Type 1 diabetes; Vaccination

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; IMMUNOMODULATING AGENT; PLACEBO;

ANTIBODY TITER; AUTOIMMUNE DISEASE; CLINICAL EVALUATION; HUMAN; IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; REGULATORY T LYMPHOCYTE; REVIEW; STANDARD; TREATMENT FAILURE; VACCINATION;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; MALE; MICE; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84869098172     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.05.005     Document Type: Review

References (35)

1. Bottazzo G.F., Florin-Christensen A., Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974, 2:1279-1283.
2. Culina S., Boitard C., Mallone R. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?. Clin Dev Immunol 2011, 2011:286248.
3. Diabetes Prevention Trial-Type 1 Diabetes Study G Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
4. Atkinson M.A., Maclaren N.K., Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990, 39:933-937.
5. Brezar V., Culina S., Gagnerault M.C., Mallone R. Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice. Eur J Immunol 2012, 42:1553-1561.
6. Sreenan S., Pick A.J., Levisetti M., Baldwin A.C., Pugh W., Polonsky K.S. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999, 48:989-996.
7. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965, 14:619-633.
8. Foulis A.K., Liddle C.N., Farquharson M.A., Richmond J.A., Weir R.S. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986, 29:267-274.
9. Foulis A.K., Farquharson M.A., Hardman R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987, 30:333-343.
10. Klinke D.J. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008, 3:e1374.
11. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007, 104:17040-17045.
12. Bingley P.J., Bonifacio E., Williams A.J., Genovese S., Bottazzo G.F., Gale E.A. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997, 46:1701-1710.
13. LaGasse J.M., Brantley M.S., Leech N.J., Rowe R.E., Monks S., Palmer J.P., et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002, 25:505-511.
14. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
15. Ludvigsson J., Krisky D., Casas R., Battelino T., Castano L., Greening J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366:433-442.
16. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
17. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005, 28:1068-1076.
18. Vehik K., Cuthbertson D., Ruhlig H., Schatz D.A., Peakman M., Krischer J.P. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011, 34:1585-1590.
19. Reijonen H., Daniels T.L., Lernmark A., Nepom G.T. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000, 49:1621-1626.
20. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
21. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
22. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
23. Yu L., Herold K., Krause-Steinrauf H., McGee P.L., Bundy B., Pugliese A., et al. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011, 60:2560-2565.
24. Axelsson S., Cheramy M., Hjorth M., Pihl M., Akerman L., Martinuzzi E., et al. Long-lasting immune responses 4 years after GAD-Alum treatment in children with type 1 diabetes. PLoS One 2011, 6:e29008.
25. Raju R., Foote J., Banga J.P., Hall T.R., Padoa C.J., Dalakas M.C., et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 2005, 175:7755-7762.
26. Harrison L.C., Honeyman M.C., DeAizpurua H.J., Schmidli R.S., Colman P.G., Tait B.D., et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993, 341:1365-1369.
27. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
28. Martinuzzi E., Novelli G., Scotto M., Blancou P., Bach J.M., Chaillous L., et al. The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes 2008, 57:1312-1320.
29. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Bello I., Cilio C.M., Wong F.S., et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 2011, 163:33-49.
30. Fourlanos S., Perry C., Gellert S.A., Martinuzzi E., Mallone R., Butler J., et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011, 60:1237-1245.
31. Moore A., Grimm J., Han B., Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 2004, 53:1459-1466.
32. Medarova Z., Tsai S., Evgenov N., Santamaria P., Moore A. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magn Reson Med 2008, 59:712-720.
33. Gaglia J.L., Guimaraes A.R., Harisinghani M., Turvey S.E., Jackson R., Benoist C., et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011, 121:442-445.
34. Wu Z., Kandeel F. Radionuclide probes for molecular imaging of pancreatic beta-cells. Adv Drug Deliv Rev 2010, 62:1125-1138.
35. Medarova Z., Moore A. MRI as a tool to monitor islet transplantation. Nat Rev Endocrinol 2009, 5:444-452.